Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201759 · ClinicalTrials.gov registry record · NA
Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)
A NA study of Spinal Cord Injury, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01201759: Completed NA study of Spinal Cord Injury, sponsored by University of Miami.
NCT01201759 is a NA study of Spinal Cord Injury that has completed, run by University of Miami. The registered enrollment target is 18 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01201759, a NA study of Spinal Cord Injury, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall study objectives are to examine whether: 1. Persons with spinal cord injury (SCI) having elevated body mass are at greater cardiovascular disease (CVD) risk for fasting and postprandial lipidemia, glycemia, and vascular inflammation than persons with SCI having 'normal' body mass, and 2. An inexpensive, low-risk, widely-available pharmacotherapy safely reduces CVD risks associated with fasting and postprandial lipidemia, glycemia, and vascular inflammation.
Primary Outcome
The postprandial lipemia is assessed by the change in the AUC for plasma triglycerides sampled before and after intervention at time points 0 (immediately post-feeding)to 480 min. For peak TG, and TG area under the curve (AUC), treatments (placebo and salsalate) and visits (pre and post treatment) were defined as within-subject's factors.
Conditions Studied
Interventions
- DRUG Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days
- DRUG Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
Study Locations (1)
Florida
- The Miami Project to Cure Paralysis - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-05 |
| Phase | NA |
What the finished NCT01201759 record still lists
NCT01201759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days is the first listed.
NCT01201759 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01201759 about?
NCT01201759 is a clinical study titled "Effects of Salsalate on Prandial-Induced Vascular Inflammation After Spinal Cord Injury (SCI)". The overall study objectives are to examine whether: 1. Persons with spinal cord injury (SCI) having elevated body mass are at greater cardiovascular disease (CVD) risk for fasting and postprandial lipidemia, glycemia, and vascular inflammation than persons with SCI having 'normal' body mass, and 2...
What is the current status of trial NCT01201759?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2009-07. Estimated completion is 2012-05.
What conditions does trial NCT01201759 study?
This clinical trial studies the following conditions: Spinal Cord Injury.
What interventions are being tested in trial NCT01201759?
The interventions under investigation include: Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days (DRUG), Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days. (DRUG).
Who is sponsoring clinical trial NCT01201759?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01201759 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01201759's enrollment target sits among peer trials
18 63rd of 99 higher than 35 of 99 other Spinal Cord Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cortical Recording and Stimulating Array Brain-Machine Interface
RECRUITING · NA
-
Clinical Outcome Assessment for AT & BCI
RECRUITING · NA
-
Motoneuron Recruitment and Motor Evoked Potential Up-Conditioning (MEP) in Spinal Cord Injury (SCI)
RECRUITING · NA
-
SCI&U Peer Health Coaching Program for Individuals Newly Discharged From Inpatient Rehabilitation
RECRUITING · NA
-
At-Home Genital Nerve Stimulation for SCI Bowel
RECRUITING · NA
-
Exoskeleton and Spinal Cord Stimulation for SCI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia